Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

I'll research this case thoroughly. Note upfront: IPR2025-00949 is a PTAB proceeding, not a district court case, so I'll verify the posture and any parallel litigation.

Let me verify the corporate backgrounds, the parallel Hatch-Waxman context, and the institution decision.

Scope note up front: despite the "patent infringement litigation" framing, IPR2025‑00949 is not a district‑court infringement suit — it is an inter partes review before the PTAB, in which Azurity Pharmaceuticals, Inc. is Petitioner and Helsinn Healthcare S.A. is Patent Owner. There is no "accused product" or district/division/judge in this proceeding; the closest analog is the Patent Owner's Orange Book–listed product (AKYNZEO) and the Hatch‑Waxman suit Helsinn previously brought against a different generic challenger, Gland Pharma. I flag what follows as sourced from PTAB filings, the PTAB docket, PACER/RECAP, and Orange Book/company materials, and I note where facts are not confirmed.

Parties. Helsinn Healthcare S.A. is a privately held Swiss pharmaceutical company (Lugano/Pazzallo; part of the Helsinn group) that commercializes the 5‑HT₃ antagonist ALOXI (palonosetron) and the NK‑1/5‑HT₃ fixed‑combination AKYNZEO (netupitant/palonosetron, oral; NDA 205718, approved Oct. 10, 2014, and the IV fosnetupitant/palonosetron form, NDA 210493, approved Apr. 19, 2018, since listed as discontinued). Helsinn is best known in patent circles as the petitioner in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. ___ (2019) (unanimous opinion holding that a confidential "secret sale" can trigger the AIA on‑sale bar). Azurity Pharmaceuticals, Inc. is a private‑equity‑backed specialty pharma (majority investor QHP Capital; HQ Woburn/Wilmington, MA; formerly CutisPharma) that reformulates and commercializes established medicines — over 50 products across ~10 therapeutic areas, with a growing oncology/supportive‑care footprint. Azurity is an operating company, not an NPE/PAE or university: it filed five coordinated IPRs against Helsinn's netupitant/palonosetron patent family in May 2025, expressly positioning itself as developing a lower‑cost CINV therapy for U.S. cancer patients. Petitioner's counsel is Wilson Sonsini Goodrich & Rosati (Richard Torczon, Jad Mills, Michael Rosato, Wendy Devine); Patent Owner's counsel is Paul Hastings LLP (Eric Dittmann, Naveen Modi, Isaac Ashkenazi, Chetan Bansal) — the same Paul Hastings team that represented Helsinn in the Gland litigation.

Patent at issue and its Hatch‑Waxman pedigree. IPR2025‑00949 challenges U.S. 10,828,297 B2, "Compositions and methods for treating centrally mediated nausea and vomiting," issued Nov. 10, 2020 from App. 15/923,050 (filed Mar. 16, 2018), inventors Trento, Cantoreggi, Rossi, Cannella, and Bonadeo, assigned to Helsinn. In one line: the '297 claims a method of preventing acute and delayed chemotherapy‑induced nausea and vomiting (CINV) in a patient on highly emetogenic chemotherapy by inducing therapeutically effective blood levels of palonosetron (5‑HT₃ antagonist) and netupitant (NK‑1 antagonist) together with dexamethasone (see claim 1). It is Orange Book–listed for AKYNZEO with a use code covering administration "in combination with dexamethasone" for acute/delayed CINV, with an estimated expiration around Dec. 17, 2030. It sits in a large Trento family; Helsinn's own briefing calls the '826 patent the "great grandparent" of the '297. The earlier Hatch‑Waxman action, Helsinn Healthcare S.A. v. Gland Pharma Ltd., No. 3:22‑cv‑04635 (ZNQ)(LHG) (D.N.J.), asserted the '297 plus nine other Helsinn patents against Gland's ANDA No. 217374 for generic IV fosnetupitant/palonosetron; Gland counterclaimed that the '297 claims were invalid over the ALOXI label, Bös, Dewan, and the EMEND label (Dkt. 25, Oct. 11, 2022), and that case ended in a consent judgment and dismissal with prejudice signed by Judge Zahid N. Quraishi on Jan. 18, 2023 (Dkt. 50), with terms largely sealed — meaning the '297's validity was never adjudicated on the merits.

Procedural posture, PTAB "venue," and why it matters. Azurity filed IPR2025‑00949 on May 1, 2025, alongside four companion petitions (IPR2025‑00945, ‑00946, ‑00947, ‑00948) targeting the related '826, '357, and '515 patents — a coordinated, multi‑front challenge to the AKYNZEO patent family. Helsinn sought discretionary denial (Paper 7, Aug. 4, 2025); Azurity opposed (Paper 8, Sept. 4, 2025). On Sept. 19, 2025, Acting Director Coke Morgan Stewart issued a single decision in the consolidated cases referring the petitions to the Board and denying discretionary denial, weighing Helsinn's "strong settled expectations" (patents in force since 2014–2020, one commercialized as an FDA‑approved product, and others asserted against a generic company) against Azurity's showing of material examiner error — i.e., that Helsinn's prosecution‑time "unexpected synergy" evidence (the netupitant/palonosetron substance‑P data and Rule 132 declarations) may have rested on a misleading comparison against aprepitant/palonosetron. That the Director found the material‑error showing sufficient to override settled‑expectations factors is the doctrinally notable feature of the case, and it is an early application of the post‑Fintiv/Advanced Bionics discretionary‑denial framework to pharma "follow‑on" patents. The Board instituted trial on Nov. 19, 2025; the merits panel is reported as Judges Michael J. Fitzpatrick, Sheridan K. Snedden, and Christopher G. Paulraj (Tech Center 1600, Art Unit 1612). The proceeding has advanced into trial — e.g., a Jan. 13, 2026 deposition of Azurity's expert, Dr. Stephen J. Peroutka (Ex. 2086 in the companion IPRs) — and, as of the latest information retrievable, no final written decision had issued; the 12‑month statutory deadline from institution runs to roughly Nov. 19, 2026. Why it matters: (1) cancellation of the '297 could remove an Orange Book barrier to generic/reformulated netupitant‑palonosetron entry, and there is currently no approved generic AKYNZEO; (2) it tests whether examiners' acceptance of "unexpected synergy" data in pharma prosecution can survive an IPR record built on the same art with adversarial testing; (3) it is a notable instance of a brand‑side specialty pharma (Azurity) using IPR offensively before any district‑court suit exists between the parties — the Director's decision expressly noted the absence of a parallel proceeding — and the briefing is unusually policy‑inflected, invoking Executive Order 14,297 on drug pricing; and (4) it illustrates the "IPR swarm" pattern, with overlapping petitions on a family of method‑of‑use patents whose validity was previously resolved only by a sealed consent judgment.

Sourcing caveats: the panel composition and Nov. 19, 2025 institution date come from PTAB docket aggregators (IP Verse/greyb and a docket‑mirror site), not from a merits institution opinion I could read directly. Public sources list both IPR2025‑00946 and ‑00947 against U.S. 9,186,357, which may be an OCR/transcription artifact; I could not confirm the specific patent numbers/titles for all four companion proceedings. I also could not confirm a specific Azurity ANDA or 505(b)(2) number for a netupitant/palonosetron product — the record describes Azurity's interest in a "price‑lowering therapy" without identifying the application, and the petition's reference to Azurity or an acquired company "working with aprepitant" is not further substantiated in the sources reviewed. Treat those points as unverified rather than established.

I'll research this. Note upfront: the case as given (IPR2025-00949) is a PTAB inter partes review, not a district court litigation — so I need to check whether there's a parallel district court action between these parties covering U.S. 10,828,297, and report both tracks. Let me search.

Now let me look for the institution decision, parallel district court litigation, and the broader IPR family.

Let me dig into the parallel district court activity, the institution decision for the '949 patent specifically, and current case status.

Threshold correction: this is a PTAB trial, not a district court litigation

The docket you gave me — IPR2025-00949, Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. — is an inter partes review before the PTAB, not a district court infringement action. There is no complaint, answer, counterclaim, Markman order, jury verdict, JMOL, or appeal in this proceeding. Almost none of the checklist you asked for maps onto it directly. Below I (a) explain what the litigation-style milestones correspond to in an IPR, (b) give the chronological record I could verify, and (c) cover the genuinely parallel/related court and PTAB proceedings, including the district court case where this patent was asserted.

Mapping of your checklist to this docket:

---

Chronological record

2025-05-01 — Azurity files five coordinated IPR petitions (filing & "pleadings" stage).
Azurity filed IPR2025-00945 ('8,623,826), -00946 and -00947 ('9,186,357), -00948 ('9,943,515), and -00949 ('10,828,297) on the same day, all targeting Helsinn's netupitant/palonosetron/dexamethasone CINV patent family (the Trento patents). In IPR2025-00949 it challenged claims 1–23 of U.S. 10,828,297 B2 on §103 obviousness. Claim 1 is a method of preventing acute and delayed nausea and vomiting in a patient on highly emetogenic chemotherapy by inducing therapeutic blood levels of palonosetron and netupitant "in a combination regimen with dexamethasone." ('297 petition excerpt: https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf; family identified in Azurity's mandatory notices: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835)/download-documents?artifactId=h-svF25LUaYKHg0RfWhu7z2zAhqSlIgvaPHQdwQ_THHfplITZ66AlVc)

• Real party in interest: Azurity Pharmaceuticals, Inc. only (no co-petitioners or privies disclosed).
• Petitioner counsel: Wilson Sonsini Goodrich & Rosati — Richard Torczon (lead, Reg. 34,448), Michael T. Rosato, Jad A. Mills, Wendy L. Devine, Garrett T. Potter.
• Patent Owner counsel: Paul Hastings — Isaac Ashkenazi and Justin Fleischacker (New York), Peter Chetan (D.C.); docket aggregators also list Eric Dittmann as respondent counsel (IPVerse: https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2025-00949).
• Expert: Dr. Stephen J. Peroutka submitted a single ~700+ page declaration (Ex. 1009) covering all four patents/five IPRs.
• Asserted art (as reflected across the family): Herrstedt (Ex. 1010) as base reference, Bös (Ex. 1014), Herrington (Ex. 1016), the ALOXI® label, plus Bonadeo and Hargreaves in dependent-claim grounds. I verified this ground structure for the '357 petition; the '297-specific ground table was not retrievable in this session — treat the exact '297 combinations as unconfirmed.

2025-08-04 — Helsinn's Patent Owner Preliminary Response + discretionary-denial request.
Helsinn did not just defend on the merits; it filed a brief (Paper 7) asking the Acting Director to deny institution on discretionary grounds under the March 26, 2025 "Interim Processes for PTAB Workload Management" memorandum. Its three pillars:

1. Settled expectations — the '297 has been in force since 2020 and is under a terminal disclaimer over U.S. 8,623,826, which issued in January 2014, so the Office itself treated the claims as "not patentably distinct."
2. §325(d) — the art (Herrstedt ≈ prosecution's "Reddy" reference; Bös is on the face of the patent) is the same or substantially the same as what the examiner considered.
3. No other forum / equity — Akynzeo® commercialization and long investment.
   (DD brief: https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557835/download-documents?artifactId=RTlVd_yjcrHsrfCr3bWtIg9K51ZwlwGCBnRJFiNe0aoy8CU5STFDBlY)

2025-09-04 — Azurity's opposition to discretionary denial (Paper 8).
Azurity argued the petitions turn on material examination error: Helsinn's Rule 132 declaration data was, in Azurity's telling, altered/selective (columns re-ordered, "not reported" entries inserted, Emend "complete protection" data omitted, Grunberg dosing differences masked), so the "unexpected synergy" basis for allowance was illusory. Azurity also argued there is no parallel district court proceeding, so Fintiv-type concerns don't apply, and invoked Executive Order 14,297 (drug-pricing policy) as a policy overlay.
(Opposition: https://www.docketalarm.com/cases/PTAB/IPR2025-00948/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/docs/09-04-2025-Petitioner/PET_Opposition_to_Discretionary_Denial_Brief-8-Petitioners_Opposition_to_Patent_Owners_Discretionary_Denial_Request.pdf)

2025-09-19 — Acting Director Stewart denies discretionary denial and refers the petitions to the Board.
A single decision (Paper 11 in each case) covered all five petitions. It weighed both ways: it credited "strong settled expectations" (patents in force since 2014/2015/2018/2020) and noted Helsinn "has asserted the patents challenged in IPR2025-00946, IPR2025-00947, and IPR2025-00949 against a generic drug company," but found (i) no currently parallel proceeding, and (ii) Azurity's material-error argument on the synergy data persuasive (e.g., that palonosetron+netupitant and palonosetron+aprepitant results were "nearly the same"). It ordered the petitions referred to the Board "to handle the cases in the normal course," and expressly barred rehearing/Director Review requests until institution decisions issued.
(Decision: https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557835/download-documents?artifactId=y6IrpDZshKUiiFxv9niHSqbJgCBiIoOXIntwhciUvoy8nIRpQCyqXDI)

2025-11-19 — Institution decisions: trial instituted in all five IPRs.
The Board (APJs Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher G. Paulraj) granted institution in IPR2025-00949 on the challenged claims of the '297, finding a reasonable likelihood of prevailing on at least one claim. The same panel instituted the four sibling IPRs the same day. (Sibling institution decision illustrating the panel/schedule: https://www.docketalarm.com/cases/PTAB/IPR2025-00948/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/docs/11-19-2025-Board/Institution_Decision__Grant-12-_Decision_Granting_Institution_of_Inter_Partes_Review.pdf) — this matches the metadata date and the "Trial Instituted" status.

2026-01-13 — Deposition of Azurity's expert (discovery milestone with strategic significance).
Dr. Peroutka was cross-examined in Palo Alto over a ~310-page confidential transcript covering all four patents and all five IPRs (filed as Helsinn Ex. 2086 in the related proceedings). Helsinn's examination went to his qualifications/currency in CINV (he stopped prescribing in ~1990; 1980s CINV research; CRO work) and to statistics/endpoint testimony — plainly laying a foundation to attack the weight of his obviousness opinions and the reliability of his "statistical significance vs. directionality" position. (Transcript: https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2025-00946/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/02-25-2026-Patent_Owner/Exhibit-2086-Exhibit_2086/)

2026-02-25 — Patent Owner Response(s) filed.
Helsinn's substantive response (with its supporting exhibits) was filed in the trial phase; the same date appears across the sibling IPR dockets (e.g., the -00946/-00947 "02-25-2026-Patent_Owner" filings). I could not independently pull the '949-specific POR document in this session — treat the '949 POR filing date as consistent-with but not independently confirmed from the '949 docket itself.

2026-03 → 2026-09 — Remaining trial phase; no dispositive event reported.
Under the Board's standard scheduling order, Petitioner's reply would be due ~3 months after the POR (roughly May 2026), Patent Owner's sur-reply ~1 month later (roughly June 2026), with the oral hearing typically set 4–8 weeks before the FWD. I found no reported oral hearing date, no settlement, no adverse judgment, and no final written decision for IPR2025-00949 in any of the sources searched. Court-level equivalents (SJ, JMOL, fees) do not exist in IPR; the only "post-trial" analogues are a rehearing request to the Board and/or an appeal to the Federal Circuit.

Statutory deadline / present posture: Final Written Decision due within 12 months of institution → by 2026-11-19 (extendable up to 6 months for good cause, 35 U.S.C. §316(a)(11)). As of today (2026-09-26), the case remains "Trial Instituted — pending," consistent with your metadata.

---

Claim construction

There was no separate Markman proceeding, and I found no express claim-construction ruling in the institution decision. In this family the construction fight is really a validity/posa battle over "therapeutically effective blood levels," "combination regimen with dexamethasone," and the claimed anti-nausea (as opposed to anti-emetic) effect. Because the Board denied institution as to nothing and instituted on the merits (rather than on §325(d) grounds), the practical center of gravity is the unexpected-results/nexus question vis-à-vis the prosecution Rule 132 data — i.e., whether Helsinn's synergy evidence survives Azurity's allegation that the underlying data were selectively presented. That is the same issue the Acting Director flagged as persuasive as to "material error."

---

Parallel and related proceedings affecting this case

1. The four sibling IPRs — the real "parallel litigation." IPR2025-00945, -00946, -00947, and -00948 (patents '826, '357 (two petitions), '515) were all filed 2025-05-01, all denied discretionary denial on 2025-09-19, and all instituted 2025-11-19 before the same panel. Azurity itself describes the '357 petition as covering "49 of 133 closely related claims spread over four patents." These five proceedings share one expert declaration and one deposition transcript, so any evidentiary/weight ruling on Dr. Peroutka in one IPR will have spillover effect on the '297. Expect coordination on appeal if outcomes diverge.

2. Helsinn Healthcare v. Gland Pharma Ltd., D.N.J. No. 3:22-cv-04635 — the only district court case in which the '297 was asserted, and it is closed. Helsinn sued Gland in July 2022 on a ten-patent family including the '297 (and '826, '357), over Gland's ANDA No. 217374 for fosnetupitant/palonosetron IV (235 mg/0.25 mg per 20 mL vials). It ended in a Consent Judgment and Dismissal Order signed by Judge Zahid N. Quraishi on 2023-01-18, dismissing all claims and counterclaims, with Gland admitting only a technical §271(e)(2)(A) act of infringement and not rebutting the statutory presumption of validity. (Order: https://www.courtlistener.com/docket/63601016/50/helsinn-healthcare-sa-v-gland-pharma-limited/) A third-party database lists a 2022-12-23 termination date for the same case — likely a data artifact or a companion docket; the operative disposition is the January 18, 2023 consent judgment. This closed case is what the Director meant by Helsinn having "asserted" the '949 patent against a generic company, and it is why the Director found no currently parallel proceeding. Note Azurity's implicit win in the discretionary-denial briefing: it argued Helsinn "paid Gland to go away" rather than prove validity — a settlement that, in a pre-Fintiv-style analysis, cuts against Helsinn.

3. No pending district court action between Azurity and Helsinn on these patents. I found no complaint by Helsinn against Azurity on netupitant/palonosetron, and no Azurity declaratory-judgment action. The IPRs appear to be a pre-emptive "clear the runway" strategy ahead of a netupitant/palonosetron product launch, which is why the absence of a parallel case was decisive. (Caveat: the specific Azurity product motivating this campaign — likely a 505(b)(2)/ANDA netupitant-palonosetron product, possibly via its Slayback Pharma affiliate, which is referenced in Delaware filings as "Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP") is my inference, not confirmed in the sources I retrieved.)

4. Distinguish the unrelated Azurity CINV litigation. The Heron Therapeutics v. Azurity/Slayback Delaware actions (CINVANTI®/APONVIE®, aprepitant) are separate — different patents, different patent owner. Azurity's IV aprepitant emulsion NDA 218754 was held to infringe claims of the '255/'520 patents, but D. Del. ruled those claims invalid under §112 on 2026-06-01, and Heron noticed an appeal and consolidated appeals on 2026-06-30/2026-07-31. Similarly, Azurity Pharms. v. Appco Pharma LLC (D. Del. 1:26-cv-00402, filed 2026-04-08) is Azurity as plaintiff on different patents. Neither bears on the '297 validity fight, but both show Azurity's aggressive litigation posture in the CINV space and are worth flagging for conflict/settlement dynamics.

5. Historical context on this patent family. Helsinn's palonosetron portfolio has been litigated for over a decade (Cipla, Hospira, Dr. Reddy's, Accord), including the on-sale-bar appeal that produced Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 586 U.S. 731 (2019). The examiner's reliance on the inventors' Rule 132 synergy declaration — the very declaration Azurity attacks here — traces to that prosecution history.

---

Bottom line on outcome and present posture

• No verdict, judgment, settlement, or appeal. IPR2025-00949 is institution-granted, trial-phase, pending; the merits have not been decided.
• Most significant legal development to date: the 2025-09-19 Acting Director decision denying discretionary denial across all five petitions — a merits-leaning application of the post-March-2025 discretionary-denial framework in which a petitioner's showing of material examination error overcame the patent owner's settled-expectations and §325(d) arguments even in a Hatch-Waxman-adjacent setting.
• Key strategic pivot: the case turns on the reliability of Helsinn's unexpected-results evidence (Rule 132 data, Emend label, Grunberg comparability), which Azurity must show the examiner never properly evaluated — and which Helsinn must defend through Dr. Peroutka's cross-examination and its own expert testimony.
• What to watch (next 2 months): (1) the Final Written Decision by 2026-11-19 for all five IPRs; (2) any request for rehearing or Director Review; (3) any Federal Circuit appeal; and (4) whether Azurity's five-front campaign produces divergent outcomes across the sibling IPRs, which would complicate any global resolution.

Sourcing caveats: The '949-specific papers (its own POR, reply, sur-reply, oral-hearing order) were not retrievable from the open docket aggregators I could reach; I verified those milestone dates from the sibling IPR dockets (-00945 through -00948) where the papers are substantively identical and cross-filed. Dates and quotes for the petition, the discretionary-denial papers, the Director decision, institution, and the Peroutka deposition are grounded in the documents linked above. The identities of Helsinn's counsel beyond the Paul Hastings attorneys of record at the January 2026 deposition, and the exact asserted grounds in the '949 petition, are not independently confirmed.

I'll research this PTAB proceeding and any parallel litigation to identify counsel of record for Azurity.

I have the power of attorney filing. Let me confirm the counsel designations in the institution decision and any later filings, plus attorney backgrounds.

Bottom line

This is a PTAB inter partes review, not a district court infringement action — so there is no "local counsel," no PACER docket, and no complaint. Azurity Pharmaceuticals, Inc. is the petitioner (the plaintiff-side party). Its counsel of record is an all-Wilson Sonsini team, designated in Petitioner's Power of Attorney (Paper 1, filed May 1, 2025) and the accompanying Mandatory Notices under 37 C.F.R. § 42.8(b)(3), with a revised counsel designation filed March 4, 2026. The Board's institution decision of November 19, 2025 lists the same team in its caption, confirming they remain counsel of record. Nothing about counsel appears to be sealed — the filings are public on PTAB's PTACTS system.

One caveat up front: the institution decision in the lead case IPR2025-00945 (Paper 11/12, Nov. 19, 2025) and Director's referral decision (Sept. 19, 2025) use a slightly shorter caption list than the power of attorney. I flag below where a name appears in one source but not another.

Counsel of record for Azurity (Petitioner)

Richard L. Torczon — Lead Counsel

• Wilson Sonsini Goodrich & Rosati, 1700 K Street NW, Floor 5, Washington, D.C. 20006. USPTO Reg. No. 34,448.
• Former Administrative Patent Judge at the PTAB (nearly two decades, authoring 1,000+ opinions and orders and helping draft the Board's rules), previously an associate solicitor in the USPTO Solicitor's Office. Senior counsel in the firm's patent litigation practice; appointed Chair of the PTAB Bar Association's Trials Committee in March 2026. Signed the petition and the § 325(d)/discretionary-denial opposition for Azurity.

Jad A. Mills — First Back-Up Counsel

• Wilson Sonsini, 701 Fifth Avenue, Suite 5100, Seattle, WA 98104. USPTO Reg. No. 63,344.
• Partner whose practice centers on PTAB proceedings. Deep life-sciences IPR bench: Mylan v. Bausch Health, Univ. of Washington v. Guardant Health, Empower Clinic Services v. Eli Lilly, Neurocrine v. Spruce Biosciences. Elected to the PTAB Bar Association board of directors in March 2026; listed as a finalist for "Post Grant Proceedings Attorney of the Year" at the 2026 LMG Life Sciences Awards.

Michael T. Rosato — Back-Up Counsel

• Wilson Sonsini, Seattle. USPTO Reg. No. 52,182.
• Veteran PTAB practitioner; listed as lead/back-up counsel in numerous life-sciences IPRs (e.g., Guardant Health, Spruce Biosciences, Mylan v. Noven, Mylan v. Bayer). Named to the Azurity team in firm and WIPR rankings coverage.

Wendy L. Devine — Back-Up Counsel

• Wilson Sonsini, One Market Plaza, Spear Tower, Suite 3300, San Francisco, CA 94105. USPTO Reg. No. 61,309.
• Co-chair of the firm's patent litigation practice; Hatch-Waxman and pharmaceutical patent strategy focus. In September 2026 named "Hatch-Waxman Litigator of the Year (Generic)" by LMG Life Sciences.

Garrett T. Potter — Back-Up Counsel

• Wilson Sonsini, Seattle. USPTO Reg. No. 76,602.
• Named in the revised March 2026 mandatory notices; part of the Wilson Sonsini team WIPR credits with the five Azurity IPR institutions.

Patrick M. Medley — Back-Up Counsel (original POA; appears superseded)

• Wilson Sonsini, 701 Fifth Avenue, Seattle (Reg. No. 74,735). Listed as back-up counsel in the initial May 1, 2025 Power of Attorney, but not in the revised counsel designation filed March 4, 2026. Treat his current status as of-record-but-superseded unless a later paper reinstates him.

Natalie Morgan — team member (not shown as of-record)

• Listed by Wilson Sonsini/WIPR among the Azurity IPR team, but she does not appear in the power of attorney, the revised mandatory notices, or the Board's caption. Likely supporting counsel rather than a designated attorney of record; I could not confirm her formal appearance.

In-house / client-side signatory (not attorney of record)

Hanok George, Chief Legal & Compliance Officer, Azurity Pharmaceuticals, Inc. — signed the Petitioner's Power of Attorney on April 30, 2025. He is the client representative, not counsel of record before the Board.

Notes and caveats

• No local counsel exists in this forum. PTAB practice has no local-counsel requirement, so none is designated.
• Helsinn's side (for contrast): Eric Dittmann, Naveen Modi, Isaac Ashkenazi, and Chetan Bansal of Paul Hastings LLP — included only to confirm the caption I'm reading matches this proceeding.
• "Plaintiff" framing. If your question was meant to capture a district court infringement suit between these parties, note that the Board's own Director-level decision states Helsinn asserted the challenged patents (including the '297 patent here) against a generic drug company, and that "the parties are not currently engaged in a parallel proceeding involving the challenged patents." So there is no Azurity-v.-Helsinn district court docket to pull counsel from. Azurity appears as a defendant in separate, unrelated Hatch-Waxman matters (e.g., Exelixis's cabozantinib litigation in D. Del., where Azurity is represented by Wilmer Cutler Pickering Hale and Dorr and Windels Marx) — different counsel, different patents, not this case.
• Sourcing. Counsel names, addresses, and registration numbers come from the public Power of Attorney and Mandatory Notices (PTACTS, Petition No. 1557835 / IPR2025-00945–00949 filings). Biographical details come from Wilson Sonsini's and IPWatchdog's published attorney bios and firm press releases (Nov. 2025 institution announcement; March 20, 2026 PTAB Bar leadership note; WIPR USA Patents 2025). I could not independently verify every individual's bar status beyond the registered numbers recited in the filings.

I'll research this. Note one important framing point up front: IPR2025-00949 is an IPR before the PTAB, not a district court infringement action, so "defendant" here means patent owner Helsinn Healthcare S.A. (the respondent/patent owner), and its counsel appear in PTAB filings rather than via a PACER docket.

Now let me find Helsinn's formal counsel designation (power of attorney/mandatory notices) and confirm the specific IPR2025-00949 filings.

Let me verify the individual attorneys' bios, the pro hac vice admissions specific to -00949, and one ambiguous name in the deposition transcript.

Threshold correction: this is an IPR, not a district court infringement case

IPR2025-00949 is an inter partes review before the PTAB. There is no PACER docket sheet, no complaint, and no "defendant" in the Rule 12 sense. The party adverse to Petitioner Azurity Pharmaceuticals, Inc. is Helsinn Healthcare S.A., the patent owner of U.S. 10,828,297 B2, and it appears in PTAB papers as "Patent Owner." Its counsel appear through PTAB mandatory notices (§ 42.8), powers of attorney, and signature blocks, not through a civil docket. Everything below is drawn from those filings.

---

Counsel of record for Helsinn Healthcare S.A. (Patent Owner)

All are at Paul Hastings LLP, which has represented Helsinn in PTAB proceedings since at least IPR2015-01554 (Aloxi®/palonosetron). Service address of record: Paul Hastings LLP, 200 Park Avenue, New York, NY 10166, tel. 212-318-6000; service email PH-Azurity-Helsinn-IPR@paulhastings.com (per Helsinn's § 42.8 Mandatory Notices, dated May 22, 2025, in the five related Azurity/Helsinn IPRs).

Board-facing panel (for context): APJs Michael J. Fitzpatrick, Sheridan K. Snedden, and Christopher G. Paulraj.

---

Caveats, gaps, and one flag

• Opposing side, for clarity: Petitioner Azurity is represented by Wilson Sonsini Goodrich & Rosati — lead counsel Richard Torczon (Washington, DC), with Jad A. Mills, Michael T. Rosato, Wendy L. Devine, Garrett T. Potter (and per WSGR/WIPR, Natalie Morgan and Patrick Medley). If your question was aimed at Azurity rather than Helsinn, that is the correct list — but as captioned, Azurity is the petitioner/plaintiff side, not the defendant.
• "Peter Chetan" anomaly: The January 13, 2026 Peroutka deposition transcript in the related cases appears at one point to list Paul Hastings counsel "BY: PETER CHETAN, ESQ. (Via Zoom), peterchetan@paulhastings.com," in the Washington, DC office. That does not match any name in Helsinn's § 42.8 notices or in the Board's signature blocks (which list Eric Dittmann, Naveen Modi, Isaac Ashkenazi, Chetan Bansal). I could not verify a "Peter Chetan" as an attorney of record, and I suspect this is a court-reporter/OCR rendering of Chetan Bansal. I am flagging it rather than asserting it as counsel.
• In-house counsel: I found no Helsinn in-house attorney designated as counsel of record in this IPR. Helsinn is a Swiss entity (Lugano, Switzerland); its PTAB filings designate only outside counsel.
• Sealed material: I did not locate any sealed filings bearing on counsel identity here, but the deposition transcript above is marked confidential, and I have not reviewed every paper in the -00945/-00946/-00947/-00948/-00949 family individually.
• Not verified: I ran out of search budget before confirming firm-bio details for Bansal, Rupert, and Fleischacker. Their role designations and registration numbers above come directly from Helsinn's § 42.8 Mandatory Notices and the Board's pro hac vice order, but their individual experience summaries are not something I can source confidently — treat those three as "role confirmed, bio unconfirmed."
• Parallel litigation context: The Director's September 19, 2025 discretionary-denial decision (Paper 11) notes Helsinn "has asserted the patents challenged in IPR2025-00946, IPR2025-00947, and IPR2025-00949 against a generic drug company" — i.e., there is a Hatch-Waxman track touching the '297 patent, though the parties are not in a parallel proceeding on this patent. Paul Hastings is Helsinn's long-standing litigation/post-grant counsel across that franchise, which is why the same core team (Dittmann, Modi, Ashkenazi) recurs.

Bottom line: For IPR2025-00949, Helsinn's counsel of record are Eric W. Dittmann (lead), Naveen Modi, Isaac S. Ashkenazi, Chetan Bansal, Melanie R. Rupert, and Justin T. Fleischacker, all of Paul Hastings LLP (New York, with Modi and Bansal also in Washington, DC), with Modi as the designated first backup and Rupert and Fleischacker admitted pro hac vice in January 2026.